What question did this study set out to answer?

To monitor hepatitis C viral RNA dynamics quantitatively before, during, and after interferon therapy in patients with chronic non-A, non-B hepatitis.

July 1, 1992Journal of Medical Virology

Hepatitis C viraemia rebound after “successful” interferon therapy in patients with chronic non‐A, non‐B hepatitis

View Full Paper

Ask AI

Bookmark

Why the study?

Does interferon therapy lead to sustained viral clearance in patients with chronic non-A, non-B hepatitis?

Population

6 patients with chronic non-A, non-B hepatitis (NANBH)

Design

Case_series

Follow-up

Up to 7 months after ending treatment

Authors

JGJeremy A. GarsonUniversity College London SBS. BrillantiUniversity of Siena CRC. RingResearch Triangle Park Foundation

Discussion

Member takes

Implication

Short-course interferon monotherapy fails to sustain HCV clearance; leaves open whether extended regimens or combinations achieve durable responses.

Key Points

To monitor hepatitis C viral RNA dynamics quantitatively before, during, and after interferon therapy in patients with chronic non-A, non-B hepatitis.
Monitored N=6 patients undergoing a 6-month course of interferon therapy for chronic non-A, non-B hepatitis.
Quantified serum hepatitis C viral RNA titers longitudinally across pre-treatment, on-treatment, and post-treatment phases using a quantitative polymerase chain reaction assay alongside alanine aminotransferase measurements.
Serum hepatitis C viral RNA was initially 10^4–10^5 genomes/ml in all patients; on therapy, viremia cleared within 1 month in 3 of 5 alanine aminotransferase responders and within several months in 2 responders, while the sole non-responder showed no viral decline.
Following discontinuation of 6-month interferon therapy, viral genome titers rapidly rebounded in all patients to levels exceeding pre-treatment baselines, followed by biochemical relapse within 7 months in all but one patient.

Structured PICO

Does interferon therapy lead to sustained viral clearance in patients with chronic non-A, non-B hepatitis?

Population

6 patients with chronic non-A, non-B hepatitis (NANBH)

Intervention

Interferon therapy for a 6-month course

Outcome

HCV viraemia levels (HCV-RNA) measured by quantitative PCRsurrogate

Interferon therapy for chronic non-A, non-B hepatitis is associated with a rapid rebound in HCV viraemia and biochemical relapse upon cessation.

Cite This Study

Garson et al. (1992) studied this question.

synapsesocial.com/papers/6a90d712cd6c08c0eacae232 https://doi.org/10.1002/jmv.1890370311

View Full Paper

Ask AI

Bookmark

Implication

Short-course interferon monotherapy fails to sustain HCV clearance; leaves open whether extended regimens or combinations achieve durable responses.

Hepatitis C viraemia rebound after “successful” interferon therapy in patients with chronic non‐A, non‐B hepatitis

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Hepatitis C viraemia rebound after “successful” interferon therapy in patients with chronic non‐A, non‐B hepatitis

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider